<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02343497</url>
  </required_header>
  <id_info>
    <org_study_id>2014-A00198-39</org_study_id>
    <nct_id>NCT02343497</nct_id>
  </id_info>
  <brief_title>Lipid-lowering Effects of an Astaxanthin Supplement in Volunteers With Mild Dyslipidaemia</brief_title>
  <acronym>LLAX</acronym>
  <official_title>Randomized, Double-blind, Placebo-controlled, Parallel-group Design, Monocentric Study on Lipid-lowering Effects of an Astaxanthin Supplement in Volunteers With Mild Dyslipidemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ajinomoto Foods Europe SAS</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Institut Polytechnique LaSalle Beauvais</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Naturalpha</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ajinomoto Foods Europe SAS</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate whether astaxanthin supplementation can impact
      triglyceride plasmatic concentrations in volunteers presenting mild dyslipidemia.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2014</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">September 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>fasting plasma triglycerides</measure>
    <time_frame>0, 12 weeks</time_frame>
    <description>g/l</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>fasting cholesterol</measure>
    <time_frame>0, 12 weeks</time_frame>
    <description>total cholesterol (g/l)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fasting HDL-cholesterol</measure>
    <time_frame>0, 12 weeks</time_frame>
    <description>g/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fasting LDL-cholesterol</measure>
    <time_frame>0, 12 weeks</time_frame>
    <description>g/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>apolipoprotein A1</measure>
    <time_frame>0, 12 weeks</time_frame>
    <description>g/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>apolipoprotein B</measure>
    <time_frame>0, 12 weeks</time_frame>
    <description>g/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>apolipoprotein balance</measure>
    <time_frame>0, 12 weeks</time_frame>
    <description>Apolipoprotein B over Apolipoprotein A1 ratio</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>resting blood pressure</measure>
    <time_frame>0, 6, 12 weeks</time_frame>
    <description>triplicate measure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>resting heart rate</measure>
    <time_frame>0, 6, 12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fasting glucose</measure>
    <time_frame>0, 12 weeks</time_frame>
    <description>g/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fasting insulin</measure>
    <time_frame>0, 12 weeks</time_frame>
    <description>mU/l</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>homeostatic model assessment to quantify insulin resistance (HOMA-IR)</measure>
    <time_frame>0, 12 weeks</time_frame>
    <description>glucose (mg/dl) * insulin(U/l) / 405</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fasting adiponectin</measure>
    <time_frame>0, 12 weeks</time_frame>
    <description>flow cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fasting leptin</measure>
    <time_frame>0, 12 weeks</time_frame>
    <description>flow cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fasting ghrelin</measure>
    <time_frame>0, 12 weeks</time_frame>
    <description>flow cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fasting resistin</measure>
    <time_frame>0, 12 weeks</time_frame>
    <description>flow cytometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>phosphatidylcholine hydroperoxides</measure>
    <time_frame>0, 12 weeks</time_frame>
    <description>HPLC/MS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasmatic concentrations in astaxanthin</measure>
    <time_frame>0, 6, 12 weeks</time_frame>
    <description>HPLC/MS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>compliance with study product</measure>
    <time_frame>0, 6, 12 weeks</time_frame>
    <description>accountability of returned used/unused caps</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
    <time_frame>during the 12 weeks of intervention</time_frame>
    <description>number of subjects with adverse events</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">68</enrollment>
  <condition>Dyslipidemias</condition>
  <arm_group>
    <arm_group_label>Astaxanthin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Astaxanthin supplement from Phaffia rhodozyma, 6mg in lipid capsules, 2 caps per day, duration 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>filling agent, in lipid capsules, 2 caps per day, duration 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Astaxanthin</intervention_name>
    <arm_group_label>Astaxanthin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        To be fulfilled at V0:

          1. Male and female volunteers, able to read and write, aged from 18 to 60 years inclusive
             at time of screening.

          2. Smokers and no smokers.

          3. Subject with a good physical condition confirmed based on the subject's interview and
             the clinical exam performed by the investigator.

          4. Subject with a Body Mass Index (BMI) ≥ 18,5 and &lt; 35 kg/m².

          5. Written informed consent provided prior to screening, after receiving and
             understanding the subject information.

          6. Stable body weight (&lt; 3% variation) within the last 3 months prior to screening.

          7. Subject registered with the French Social Security, in agreement with the French law
             on biomedical experimentation.

             To be fulfilled before V1, randomization visit:

          8. Subject with fasting triglyceride concentration ≥ 1.2 and &lt; 4 g/l.

          9. Subject with fasting serum LDL-cholesterol ≤ 2.2 g/l.

        Exclusion Criteria:

        To be fulfilled at V0:

          1. Subject taking lipid altering drug therapy within 6 weeks prior to screening. Also
             excluded are supplements known to have significant lipid altering effects, such as:

               -  Phytosterols or phytostanols,

               -  Red yeast rice extract (Monascus purpureus),

               -  Beta-glucans,

               -  Omega-3 fatty acids (alpha-linolenic, docosahexaenoic and eicosapentaenoic),

          2. Subject using the following medications: systemic corticosteroids (nasal and inhaled
             corticosteroids are permitted), orlistat, bile acid resins, prescription omega-3 fatty
             acids, cyclical or non continuous hormone therapy (estrogen or testosterone) excepted
             stable oestroprogestative or progestative contraception i.e. started at least three
             months preceding the screening visit.

          3. Intake of oestroprogestative or progestative contraception started within less than
             three months preceding the screening visit.

          4. Subject taking antioxidant agents or vitamins within 6 weeks prior to screening.

          5. Subject taking astaxanthin-rich foods (red fish and seafood, mostly) or supplements
             (including krill).

          6. Subject following any special diet including, but not limited to liquid, high or low
             protein, raw food, vegetarian or vegan, etc.

          7. Subject with any sensitivity or allergy to any of the products used in this clinical
             trial.

          8. Subject that consume more than three (3) units of alcoholic beverage daily. For the
             purpose of this study, a unit of alcohol is defined as 400 ml of beer, 200 ml of wine
             or 50 ml of hard spirits.

          9. Subject with known human immunodeficiency virus (HIV) seropositivity.

         10. Women who are pregnant or breastfeeding, or planning a pregnancy during the duration
             of the study.

         11. Female subject without efficient contraceptive method: hormonal contraception
             (including patch, contraceptive ring, etc.), intra-uterine device or other mechanical
             contraception method (condom or diaphragm) or spermicide for all the duration of the
             study.

         12. Subject treated for type 1 or type 2 diabetes mellitus.

         13. Subject with known cardiovascular disease or stroke, except for conditions that are
             deemed clinically insignificant by the investigator.

         14. Subject with symptomatic hypertension, treated or not.

         15. Subject treated by antivitamin K.

         16. Subject with history of significant gastrointestinal disease such as severe
             constipation, diarrhea, malabsorptive disease, inflammatory bowel disease (e.g.
             Crohn's disease, ulcerative colitis) and all kind of gastrointestinal surgery.

         17. Subject with thyroid dysfunction or treatment for this pathology.

         18. Subject with history of severe psychiatric illness which in the opinion of the
             investigator would interfere with the optimal participation in the study.

         19. Subject with history of cancer within 5 years of screening visit (except for
             successfully treated basal and squamous cell carcinoma of the skin).

         20. Subject with any medical contraindication to blood sampling (anemia, clotting defect).

         21. Subject practicing intense physical activity (sport, physical exertion at work).

         22. Subject with history of drug abuse.

         23. Participation to any other clinical trial simultaneously and/or within 1 month prior
             to screening.

         24. Subject who in the opinion of the investigator have a risk of non-compliance to the
             study procedures or who are otherwise not appropriate to include in this clinical
             trial.

         25. Subject of legal age unable of giving consent.

         26. Subject deprived of liberty by judicial or administrative decision.

         27. Subject of legal age under legal protection.

         28. Subject having received over 4500 euros for clinical trial participation within the
             prior year including the indemnity for the present study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Centre Nutrition Clinique Naturalpha</name>
      <address>
        <city>Lille</city>
        <zip>59020</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2015</study_first_submitted>
  <study_first_submitted_qc>January 16, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2015</study_first_posted>
  <last_update_submitted>January 8, 2018</last_update_submitted>
  <last_update_submitted_qc>January 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dyslipidemias</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

